RAPID-2. A Study to Evaluate the Effectiveness of Alternate Dosing of PROCRIT (Epoetin Alfa) in Maintaining Hemoglobin Levels in Patients With Chemotherapy Related Anemia

NCT00495378 · clinicaltrials.gov ↗
PHASE4
Phase
TERMINATED
Status
25
Enrollment
INDUSTRY
Sponsor class

Stopped This study was stopped due to slow enrollment after enrolling 25 of 200 patients.

Conditions

Interventions

Sponsor

Ortho Biotech Products, L.P.